Project Grant R37AI195421
Award Date 8/14/25
Completion Date 7/31/30
Dollars Obligated $891K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Philadelphia, PA 19104, USA
Similar Awards
- This Project Grant award of $486,057 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports the development of a multipronged mRNA gene therapy approach to address challenges in achieving an HIV cure. The award aims to develop three novel mRNA-based interventions: targeted delivery of the viral protein Tat to activate HIV transcription, hepatic delivery of mRNA encoding HIV-neutralizing...
- This federal Cooperative Agreement award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $4,211,839 to The Trustees of the University of Pennsylvania to develop a germline-targeting priming immunogen for the HIV envelope V2-apex broadly neutralizing antibody (bnAb) site. The primary goal is to test the ability of this rationally designed targeted immunogen to activate V2-apex bnAb...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,379,954 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Scripps Research Institute. The grant, awarded on August 21, 2025, supports research to engineer durable immunity by optimizing HIV vaccine parameters to drive long-lived plasma cell development. The project aims to systematically study the effects of immunogen affinity, valency, adjuvants, vaccine platforms, and...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $3,568,644 Cooperative Agreement under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Wistar Institute of Anatomy and Biology, a non-profit biomedical research institute. The award aims to develop an individualized HIV cure strategy that combines enhanced neutralizing antibody responses, antiviral adaptive NK cells, and engineered cell-mediated effector strategies. The goal is to characterize...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $822,015 Project Grant titled "NOVEL STATISTICAL METHODS FOR CONFOUNDED AND INCOMPLETE NETWORK DATA" to the University of Pennsylvania. This grant, provided under the NIAID's Allergy and Infectious Diseases Research program (CFDA 93.855), will fund the development of new statistical methodologies to address challenges posed by missing data, confounding, and complex social network structures in studies of public...
- This federal Project Grant award of $4,630,686 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research to develop an effective HIV vaccine. The primary goal is to stimulate B cell lineages capable of producing broadly neutralizing antibodies (bnAbs) against diverse HIV strains, a key challenge in traditional vaccine approaches. The research involves preclinical studies in non-human primates using the BG505...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to develop a multivalent mRNA HIV vaccine that can elicit broadly neutralizing antibodies targeting the conserved envelope (Env) region of recently circulating subtype C HIV strains. The central hypothesis is that priming with a single Env immunogen followed by boosting with a multivalent Env immunogen set...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $910,905 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Scripps Research Institute in La Jolla, CA. The grant, awarded on July 1, 2025, supports the development of an HIV vaccine using a lipid nanodisc platform to incorporate the envelope (Env) glycoprotein of HIV. The project aims to enable scalable and reproducible in vitro characterization and optimization of engineered...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,275,484 Cooperative Agreement to Weill Medical College of Cornell University on August 12, 2025 under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855). The goal of this project is to identify an optimal prime-boost immunization strategy to guide antibody maturation towards broad neutralization of HIV in early life. The project aims to: 1) Compare sequential versus simultaneous...
- This Project Grant, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), provides $1,285,304 to the Scripps Research Institute to conduct research on developing a durable broadly neutralizing antibody (bnAb) response for an HIV vaccine. The key objectives are to: Assess the durability of a 6-shot sequential vaccine regimen that induces bnAb responses in non-human primates. Evaluate the...